Objective:To investigate the effects of Jianpijiedutang combined with Kangfuxin Liquid in the treatment of recurrent oral ulcer(ROU).Methods:80 patients with ROU were divided into 2 groups(n=40).The patients in control group were treated with Kangfuxin Liquid local spray,those in the test group were treated with Jianpijiedutang combined with Kangfuxin Liquid spray.The patients were followed up for 24 weeks.The effects were evaluated according to the trial standard of Chinese Stomatological Association.Results:The interval of ROU increased and ulcer number decreased in the 2 groups during the observation period,the test group showed more effective outcome than the control group(P<0.05).In the treatment group ROU interval increased more than in the control group(P<0.01),and ROU ulcer number decreased more(P<0.01).Conclusion:The Jianpijiedutang combined with Kangfuxin Liquid spray is more effective than the latter used only.

To analyze the distribution of traditional Chinese medicine constitution types in elderly patients with insomnia.

Objective To review the research progress, present the research status and analyze the evolution trend of hot spots through the bibliometric analysis of the research literature of cancer-related fatigue(CRF) at home and abroad. Methods We took CRF as the theme and the papers on CRF included in CNKI and WOS core database as the research object, and used VOSviewer and CiteSpace software as research tools, to make a visual atlas analysis on the research status and hot spot evolution at home and abroad. Results (1)Research status: ① Literature: 3 646 papers (1 959 in English and 1 687 in Chinese) were finally included. The number of papers published at home and abroad showed an overall upward trend, and the proportion of foreign fund papers was high; ② domestic papers focused on nursing and rehabilitation. The research area of foreign papers was more extensive, diverse and integrated; ③ Domestic cooperation was mainly small group cooperation, while foreign cooperation was more interdisciplinary and cross-team cooperation, forming a number of core teams and research institutions; ④ Domestic scholars paid attention to clinical application research and were good at learning from foreign countries and summarizing own experience. Foreign scholars paid more attention to basic research and the treatment was more systematic and standardized; ⑤ There were a variety of diagnostic and therapeutic evaluation tools, mainly foreign scales. (2) Hot spot evolution: "quality of life" had always been a common topic of concern at home and abroad. Domestic scholars focused on clinical research and emphasized "treatment based on examination of causes" and "treatment based on syndrome differentiation". Foreign scholars attached importance to basic research and methodological research, and advocated non-drug intervention such as sports. In recent years, complementary and alternative medicine had become a hot topic in the international research. Domestic scholars had paid more attention to the research of mechanism and methodology, and expanded the application of TCM characteristic therapy in CRF. Conclusion Integrated traditional Chinese and Western medicine and multi-disciplinary participation are the future diagnosis and treatment mode of CRF. It's the direction of future efforts to establish CRF evaluation and management mode with TCM characteristic non-drug therapy as the core under integrated medicine.

BACKGROUND AND OBJECTIVEResults of studies on genetic polymorphisms of ERCC1 gene in DNA repair pathway which may affect response to platinum-based chemotherapy and survival in patients with non-small cell lung cancer are conflicting. The aim of this study is to prospectively assess the association between single nucleotide polymorphisms of C8092A and codon118 in ERCC1 and drug response in 90 patients with advanced non-small cell lung cancer treated with cisplatin-based chemotherapy.

METHODSAll patients were treated with cisplatin-based chemotherapy. Genotypes of ERCC1 C8092A and codon118 were examined by sequencing, and the association between genotypes and response was evaluated.

RESULTSGenotype frequencies of ERCC1 C8092A were CC 40.0% (36/90), CA 48.9% (44/90) and AA 11.1% (10/90), frequencies of codon118 were CC 58.9% (53/90), CT 34.4% (31/90) and TT 6.7% (6/90). There was no significant difference in response rate of patients carrying with CC, compared with CA plus AA in C8092A (33.3% vs 29.6%, P = 0.71). Response rate of patients carrying with CC in ERCC1 118 was 32.1%, 24.3% with CT plus CC (P = 0.43). There was no difference in progression free survival between patients carrying with CC and CT plus TT in C8092A (5.2 months vs 5.4 months, P = 0.62). There was no difference in progression free survival between patients carrying with CC and CA plus AA (5.5 months vs 5.3 months, P = 0.59).

CONCLUSIONThe results suggest that there is no association between polymorphisms in ERCC1 C8092A and codon118 and response in patients with advanced non-small cell lung cancer receiving cisplatin-based chemotherapy.

Adult ; Aged ; Antineoplastic Agents ; therapeutic use ; Carcinoma, Non-Small-Cell Lung ; drug therapy ; genetics ; mortality ; Cisplatin ; therapeutic use ; DNA-Binding Proteins ; genetics ; Disease-Free Survival ; Endonucleases ; genetics ; Female ; Genotype ; Humans ; Lung Neoplasms ; drug therapy ; genetics ; mortality ; Male ; Middle Aged ; Polymorphism, Genetic ; genetics ; Prospective Studies

BACKGROUNDTo evaluate the efficacy and toxicity of combined chemotherapy of domestic paclitaxel and vinorelbine plus cisplatin and carboplatin in the treatment of advanced non-small cell lung cancer (NSCLC).

METHODSA total of 181 initially treated patients with advanced NSCLC were enrolled in this study and treated by NP (vinorelbine plus cisplatin), TC (domestic paclitaxel plus carboplatin) and TP (domestic paclitaxel plus cisplatin). The efficacy and side effects were analysed after at least two cycles of chemotherapy.

RESULTSThe overall response rates (CR+PR) were 42.4% in the NP arm, 40.3% in the TC arm and 43.3% in the TP arm respectively. No significant statistical difference was found among the three groups ( Chi-square= 0.108 6 , P > 0.05). The median survival times were 8.4 months, 9.4 months and 8.9 months respectively in the NP, TC and TP groups ( P > 0.05). The 1-, 2-, 3-year survival rates were 39.0%, 16.9%, 5.1% in the NP group and 41.9%, 21.0%, 6.5% in the TC group and 40.0%, 18.3%, 5.0% in the TP group respectively. No significant statistical difference was found among the three groups ( Chi-square=0.140 4, P > 0.05). The major side effects were myelosuppression, alopecia and nausea/vomiting in the three groups. There were no chemotherapy-related death among the three groups.

CONCLUSIONSThe combined regimens of NP, TC and TP are effective and well-tolerated regimens for advanced NSCLC.

BACKGROUNDTopotecan is one of active agents for relapsed small cell lung can-cer (SCLC), some studies have shown that it is effective against SCLC as the first-line drug. This study is to assess the efficacy, toxicity and survival rate of topotecan plus cisplatin (TP) versus etoposide plus carboplatin (CE) in patients with previously untreated SCLC.

METHODSSixty-four patients with previously untreated SCLC were randomly assigned to receive either TP or CE. Topotecan 0.75 mg/(m²×d) via a 30-min intravenous infusion on days 1 to 5 and cisplatin 25 mg/(m²×d) on days 1 to 3 with hydration were given to patients in TP group. Carboplatin 300 mg/m² on day 1 and etoposide 100 mg/d on days 1 to 5 were given to patients in CE group. Treatment was repeated every 21 days. Responses and toxicities were evaluated in patients who received two cycles of chemotherapy. Patients with limited disease SCLC received thoracic irradiation or operation after the completion of chemotherapy.

RESULTSOverall response rate was 75.0% in TP group and 68.8% in CE group. The median survival time was 10.5 months in TP group and 9.6 months in CE group. 1-, 2- and 3-year survival rate were 40.6%, 18.8% and 9.4% in TP group and 34.4%, 15.6% and 9.4% in CE group respectively. There were no significant differences in response rate, median survival time and survival rate between two groups (P > 0.05). Myelosuppression, nausea and vomiting, and alopecia were the most common toxicities, there was no significant difference in grade III and IV toxicities between two groups (P > 0.05).

CONCLUSIONSTP has similar response rate and survivals with CE, and its toxicities are acceptable. TP regimen is an effective first-line treatment for SCLC.

OBJECTIVE：To invest igtae the rationality of drug use of pregnant women in the outpatient department of our hospital，and to promote rational drug use in the clinic. METHODS ：The prescriptions of pregnant women in Beijing Shijitan Hospital Affiliated to Capital Medical University from Jan. to Dec. in 2019 were extracted by using hospital information management system ，and then analyzed statistically in respects of drug varieties ，DDDs，safety grading ，and use of Chinese patent medicine. RESULTS ：The most frequently used drugs in obstetric outpatients were vitamins and microelements ，followed by blood system and hormone drugs. Grade B drugs with good safety were most used ，the use of ungraded drugs were reasonable ，and grade X drugs were not used. There were 6 kinds of Chinese patent medicines used for pregnant women ，of which 2 kinds were marked “usable”in the drug instructions ，4 kinds were not marked in the dug instructions ，and the Chinese patent medicines that were not marked“prohibited”and“cautious”in the drug instructions were not used. CONCLUSIONS ：The drug use of pregnant women are generally reasonable in outpatient department of our hospital. The safety of some Chinese patent medicine used during pregnancy still needs to be further confirmed.

Enhancing remyelination after injury is of utmost importance for optimizing the recovery of nerve function. While the formation of myelin by Schwann cells (SCs) is critical for the function of the peripheral nervous system, the temporal dynamics and regulatory mechanisms that control the progress of the SC lineage through myelination require further elucidation. Here, using in vitro co-culture models, gene expression profiling of laser capture-microdissected SCs at various stages of myelination, and multilevel bioinformatic analysis, we demonstrated that SCs exhibit three distinct transcriptional characteristics during myelination: the immature, promyelinating, and myelinating states. We showed that suppressor interacting 3a (Sin3A) and 16 other transcription factors and chromatin regulators play important roles in the progress of myelination. Sin3A knockdown in the sciatic nerve or specifically in SCs reduced or delayed the myelination of regenerating axons in a rat crushed sciatic nerve model, while overexpression of Sin3A greatly promoted the remyelination of axons. Further, in vitro experiments revealed that Sin3A silencing inhibited SC migration and differentiation at the promyelination stage and promoted SC proliferation at the immature stage. In addition, SC differentiation and maturation may be regulated by the Sin3A/histone deacetylase2 (HDAC2) complex functionally cooperating with Sox10, as demonstrated by rescue assays. Together, these results complement the recent genome and proteome analyses of SCs during peripheral nerve myelin formation. The results also reveal a key role of Sin3A-dependent chromatin organization in promoting myelinogenic programs and SC differentiation to control peripheral myelination and repair. These findings may inform new treatments for enhancing remyelination and nerve regeneration.
Animals ; Axons ; Chromatin/metabolism* ; Gene Expression Profiling ; Myelin Sheath/metabolism* ; Nerve Regeneration/physiology* ; Rats ; Schwann Cells/metabolism* ; Sciatic Nerve/injuries*